|
IGI, Inc. announced today that Manhattan Pharmaceutical has initiated the Phase 2a clinical study for PTH (1-34) topical product. IGI licensed PTH 1-34 to Manhattan Pharmaceuticals in April of 2004
BUENA, NJ, USA | November 9, 2007 | IGI, Inc. (AMEX:IG) announced today that Manhattan Pharmaceutical has initiated the Phase 2a clinical study for PTH (1-34) topical product. IGI licensed PTH 1-34 to Manhattan Pharmaceuticals in April of 2004. This U.S. multi-center, randomized, double-blind, vehicle-controlled, parallel group study is designed to evaluate safety and preliminary efficacy of topical PTH (1-34) for the treatment of psoriasis. Approximately 54 subjects will be enrolled and randomized to receive one of two dose levels of topical PTH (1-34), or vehicle, for an 8 week treatment period.
According to the National Psoriasis Foundation nearly 2% of the worldwide population, including approximately 4.5 million Americans, suffers from psoriasis. In the U.S. psoriasis patients are responsible for nearly 2.4 million visits to dermatologists each year with an annual cost of nearly $3 billion. The topical psoriasis therapeutics market is estimated to be $ 1 billion worldwide.
This report contains forward-looking statements relating to IGI's hopes and expectations for the future. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, words such as "will," "possible," "one time," "provides an opportunity," "continue" and similar expressions are intended to identify forward-looking statements. Such statements involve a number of risks and uncertainties and actual future events and results could differ materially from those indicated by such forward-looking statements due to general economic conditions, and the risk factors detailed in IGI's periodic reports and registration statements filed with the Securities and Exchange Commission.
SOURCE: IGI, Inc. |
